We could not find any results for:
Make sure your spelling is correct or try broadening your search.
WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -4.24 | -20.7334963325 | 20.45 | 21.13 | 14.97 | 474779 | 18.21329057 | CS |
4 | -1.26 | -7.21236405266 | 17.47 | 24.975 | 14.97 | 279076 | 19.82249572 | CS |
12 | -5.29 | -24.6046511628 | 21.5 | 29.3 | 14.97 | 321270 | 22.5700444 | CS |
26 | -5.29 | -24.6046511628 | 21.5 | 29.3 | 14.97 | 321270 | 22.5700444 | CS |
52 | -5.29 | -24.6046511628 | 21.5 | 29.3 | 14.97 | 321270 | 22.5700444 | CS |
156 | -5.29 | -24.6046511628 | 21.5 | 29.3 | 14.97 | 321270 | 22.5700444 | CS |
260 | -5.29 | -24.6046511628 | 21.5 | 29.3 | 14.97 | 321270 | 22.5700444 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions